Mylan Cautions Investors Over Sell-Side Analysts' Estimates
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a surge in trading volume due to Carl Icahn's clearance to purchase up to 11.9% of Mylan stock, the company says that analysts' estimates may not reflect negative changes in the generic industry. Mylan plans to provide guidance "as soon as practically possible."
You may also be interested in...
Mylan Sues FDA, Seeks Injunction Against Macrobid “Authorized” Generic
The lawsuit, filed in Clarksburg, W.Va. federal court, says authorized generic deals “deter competition by discouraging challenges to even the weakest patents.”
“Authorized” Generics Fight Moves To Capitol Hill, FTC
Mylan plans to meet with Hill staffers, members of Congress to lay the groundwork for legislation against “authorized” generic deals. The company is leading efforts of generic firms who are trying to persuade FTC that authorized generics do not save consumers money and result in fewer patent challenges.
Mylan’s Duragesic Generic Cannot Escape J&J’s Pediatric Exclusivity – Court
D.C. federal judge upholds FDA’s determination that the generic fentanyl patch cannot come to market until after pediatric exclusivity expires in January.